India SEBI Regulatory Enforcement Actions — May 20, 2026
The 18 filings in this stream paint a mixed picture of the Indian regulatory and corporate landscape, dominated by a handful of high-impact events. The most significant theme is **Sammaan Capital's strategic transformation**: despite reporting a massive ₹8,101-crore net loss (driven by a ₹6,499-crore exceptional charge and portfolio repositioning), the company secured an ₹8,850-crore equity infusion from IHC and received a full sweep of credit rating upgrades (CRISIL, CARE, ICRA) to 'AA+/Stable' within 50 days, signaling a successful balance sheet cleanup. **Apollo Hospitals** shows robust full-year growth (+13.7% revenue, +15.1% PAT) but a clear sequential slowdown in Q4 (+3.2% revenue QoQ), coupled with strategic divestments of its fertility and specialty hospital chains to Kids Clinic India for ₹15,500 crore EV—a move to unlock value. **Bharti Airtel** reported a lifetime-high consolidated revenue of ₹2.11 lakh crore, but its India mobile ARPU growth was disappointing (+₹3 to ₹257), with management calling it unsatisfactory due to international roaming headwinds. **Fine Organic Industries** delivered a mixed result with Q4 PAT surging 21% YoY but full-year EBITDA declining 5.8% due to raw material cost pressures, while announcing a strategic acquisition in Malaysia. Several specialty chemical companies (DCM Shriram Fine Chemicals, Gandhar Oil, Camlin Fine Sciences) are reporting financial results for the fiscal year, with DCM showing a sharp net profit decline (from ₹1,845 Lakh to ₹429 Lakh). The period-comparison data reveals a sector-wide theme of **cost inflation and margin compression** across healthcare and chemicals, while the **capital allocation pattern** favors dividends (Apollo, DCM, Bharti, NGL Fine-Chem) and debt-raising (Sammaan up to ₹10,000 crore) over buybacks.